Skip to main content

HubXchange

HubXChange logo

Oligonucleotides & Peptides Xchange - San Francisco - 2025

Page Banner 1

  1. Regulatory, Safety & Market Access
    • Regulatory, Safety & Market Access
    Innovative Drug Delivery Platforms To Enhance Efficacy And Reduce Side Effects
  2. Peptide CMC & Process Development
    • Peptide CMC & Process Development
    Poster Presentation:
  3. Regulatory, Safety & Market Access
    • Regulatory, Safety & Market Access
    Sponsored Roundtable:
  4. Regulatory, Safety & Market Access
    • Regulatory, Safety & Market Access
    Innovative Drug Delivery Platforms To Enhance Efficacy And Reduce Side Effects
  5. Innovation in Therapeutic Modalities
    •  Innovation in Therapeutic Modalities
    Oligo-peptide conjugates & delivery technologies
  6. Translational & Clinical Strategy
    • Translational & Clinical Strategy
    Poster Presentation:
  7. Innovation in Therapeutic Modalities
    •  Innovation in Therapeutic Modalities
    Sponsored Roundtable:
  8. Peptide CMC & Process Development
    • Peptide CMC & Process Development
    Sponsored Roundtable:

    YMC America

  9. Peptide CMC & Process Development
    • Peptide CMC & Process Development
    Industry Roundtable:
  10. Translational & Clinical Strategy
    • Translational & Clinical Strategy
    Explore how the GLP-1 class (e.g., semaglutide) evolved from a diabetes drug to a global metabolic health blockbuster
  11. Oligonucleotide CMC & Process Development
    • Oligonucleotide CMC & Process Development
    Latest Strategies For Ensuring Robust QC Processes During Manufacturing And Scaling
  12. Regulatory, Safety & Market Access
    • Regulatory, Safety & Market Access
    Poster Presentation:
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Afternoon Refreshments
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Spotlight Presentation:
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Evening Drinks Reception
  16. Oligonucleotide CMC & Process Development
    • Oligonucleotide CMC & Process Development
    Poster Presentation:
  17. Innovation in Therapeutic Modalities
    •  Innovation in Therapeutic Modalities
    Poster Presentation:
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Opening Address & Keynote Presentation:
    Opening Address & Keynote Presentation:
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    1-2-1 Meetings/Networking Break
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    1-2-1 Meetings/Networking Break
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Networking Lunch
  22. Translational & Clinical Strategy
    • Translational & Clinical Strategy
    Sponsored Roundtable:
  23. Oligonucleotide CMC & Process Development
    • Oligonucleotide CMC & Process Development
    Sponsored Roundtable:

    ChemGenes

    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Morning Refreshments
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    1-2-1 Meetings/Networking Break
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    1-2-1 Meetings/Networking Break
  27. Peptide CMC & Process Development
    • Peptide CMC & Process Development
    Peptide Process Scale-Up: Overcoming Development Hurdles
    •  Innovation in Therapeutic Modalities
    • Translational & Clinical Strategy
    • Oligonucleotide CMC & Process Development
    • Peptide CMC & Process Development
    • Regulatory, Safety & Market Access
    Registration
  29. Translational & Clinical Strategy
    • Translational & Clinical Strategy
    Explore how the GLP-1 class (e.g., semaglutide) evolved from a diabetes drug to a global metabolic health blockbuster.
  30. Innovation in Therapeutic Modalities
    •  Innovation in Therapeutic Modalities
    Novel Therapeutic Modality: Endogenous Circular DNAs in Human Cells
    Circular DNA exists as an endogenous molecule in human cells with emerging relevance to health and d ...
    Massa Shoura
    Massa Shoura, Co-Founder, CEO & CSO
  31. Oligonucleotide CMC & Process Development
    • Oligonucleotide CMC & Process Development
    Ensuring Robust QC Processes During Manufacturing And Scaling
    Manufacturing of long RNA oligos: Synthesis and analytical strategies and challenges  Scaling Up Oli ...
    Khiem Nguyen
    Khiem Nguyen, Director Oligonucleotide Process Development - Ultragenyx
Search